Quest for the right Drug
ליורזל 25 מ"ג טבליות LIORESAL 25 MG TABLETS (BACLOFEN)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects LIO API MAY24 V2 Page 5 of 10 Adverse effects occur mainly at the start of treatment (e.g. sedation, somnolence and nausea), if the dosage is raised too rapidly, if large doses are employed, or in elderly patients. They are often transitory and can be attenuated or eliminated by reducing the dosage; they are seldom severe enough to necessitate withdrawal of the medication. Should nausea persist following a reduction in dosage, it is recommended that Lioresal be ingested with food or a milk beverage. In patients with a history of psychiatric illness or with cerebrovascular disorders (e.g. stroke) as well as in elderly patients, adverse reactions may assume a more serious form. Lowering of the convulsion threshold and convulsions may occur, particularly in epileptic patients. Certain patients have shown increased spasticity as a paradoxical reaction to the medication. An undesirable degree of muscular hypotonia - making it more difficult for patients to walk or fend for themselves - may occur and can usually be relieved by re-adjusting the dosage (i.e. by reducing the doses given during the day and possibly increasing the evening dose). Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000) very rare (< 1/10,000) and Not known (cannot be estimated from the available data). Table 1 Tabulated summary of adverse drug reactions Immune system disorders Not known: Hypersensitivity Nervous system disorders Very common: Sedation, somnolence Common: Respiratory depression, confusional state, dizziness, hallucination, depression, fatigue, insomnia, euphoric mood, muscular weakness, ataxia, tremor, nightmare, myalgia, headache, nystagmus, dry mouth Rare: Paraesthesia, dysarthria, dysgeusia Unknown: Sleep Apnoea syndrome* Eye disorders Common: Visual impairment, accommodation disorder Cardiac disorders Common: Cardiac output decreased Not known: Bradycardia Vascular disorders Common: Hypotension Gastrointestinal disorders Very common: Nausea Common: Gastrointestinal disorder, constipation, diarrhoea, retching, vomiting Rare: Abdominal pain Hepatobiliary disorders Rare: Hepatic function abnormal LIO API MAY24 V2 Page 6 of 10 Skin and subcutaneous tissue disorders Common: Rash, hyperhidrosis Not known Urticaria, alopecia Renal and urinary disorders Common: Pollakiuria, enuresis, dysuria Rare: Urinary retention Reproductive system and breast disorders Rare: Erectile dysfunction Not known: Sexual dysfunction General disorders and administration site conditions Very rare Hypothermia Not known Drug withdrawal syndrome* (see section 4.4) , swelling face and peripheral oedema Investigations Not known: Blood glucose increased *Drug withdrawal syndrome including postnatal convulsions in neonates has also been reported after intra-uterine exposure to oral Lioresal. * Cases of central sleep apnoea syndrome have been observed with baclofen at high doses (≥ 100 mg) in patients who are alcohol dependent. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
שימוש לפי פנקס קופ''ח כללית 1994
Spasticity associated with multiple sclerosis, spinal cord injuries and spinal cord diseases
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
עלון מידע לצרכן
29.12.19 - עלון לצרכן אנגלית 19.04.22 - עלון לצרכן אנגלית 19.04.22 - עלון לצרכן עברית 29.12.19 - עלון לצרכן ערבית 19.04.22 - עלון לצרכן ערבית 13.05.24 - עלון לצרכן עברית 23.07.24 - עלון לצרכן אנגלית 23.07.24 - עלון לצרכן ערבית 11.11.12 - החמרה לעלון 29.12.19 - החמרה לעלון 01.03.22 - החמרה לעלון 13.05.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
ליורזל 25 מ"ג טבליות